Previous 10 | Next 10 |
2023-05-23 17:06:29 ET Summary Cassava stock - incredibly volatile between 2020-2022 - hasn't increased much in value in the last year. The company's Alzheimer's candidate Simufilam remains in Phase 3 studies with data likely arriving in 2024. The company remains heavily short...
2023-05-18 10:59:22 ET S3 Partners dug into the short interest data on U.S. stocks to find the names that are seeing the most pressure exerted on investors with short positions. Ihor Dusaniwsky filtered the stock universe to pull out squeeze candidates with over $50M worth of short inte...
2023-05-16 14:56:55 ET Summary Blarcamesine, Aricept, and most probably simufilam are sigma-1 receptor agonists. Sigma-1 receptor agonists often produce temporary improvements in cognition for those with mild cognitive impairment and can initially stabilize the disease in mild Alz...
2023-05-14 12:00:49 ET Leqembi, the new Alzheimer's therapy developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), could add $2B - $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study. Early th...
2023-05-12 16:39:19 ET Shares of Cassava Sciences (NASDAQ: SAVA) were up 18.7% for the week, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech stock closed at $22.32 last week, then rose to as high as $28.65 on Thursday, the day th...
The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease. Primary Outcome Measures Are Safety and Change in Cognition Scores. Top-line Clinical Results of the CMS Are Expected in Q3 20...
2023-05-10 12:04:07 ET Summary Shorts have targeted the small biotech as a one-trick pony. Evidential data for simufilam’s biological activity outside the field of neurodegeneration promised by mid-year arrived early. Milan researchers found that simufilam increases the...
New in vitro data from Europe show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling. Data suggest FLNA is a central factor influencing pituitary tumor cell behavior. Data to be presented at the Europea...
2023-05-01 18:06:45 ET Cassava Sciences ( NASDAQ: SAVA ) has filed for a mixed securities shelf offering. The amount has not been determined. The filing does not necessarily indicate that a sale has begun or will occur in the future. The company indicated it plans to use t...
2023-05-01 10:41:18 ET Cassava Sciences press release ( NASDAQ: SAVA ): Q1 GAAP EPS of -$0.58. At March 31, 2023, cash and cash equivalents were $187.5 million, with no debt. For further details see: Cassava Sciences GAAP EPS of -$0.58
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...